Details
Stereochemistry | ACHIRAL |
Molecular Formula | C17H12ClF3N2O |
Molecular Weight | 352.738 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
FC(F)(F)CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C3=CC=CC=C3
InChI
InChIKey=WYCLKVQLVUQKNZ-UHFFFAOYSA-N
InChI=1S/C17H12ClF3N2O/c18-12-6-7-14-13(8-12)16(11-4-2-1-3-5-11)22-9-15(24)23(14)10-17(19,20)21/h1-8H,9-10H2
DescriptionSources: https://www.drugs.com/mtm/paxipam.htmlCurator's Comment: description was created based on several sources, including:
http://www.wikidoc.org/index.php/Halazepam | http://www.pharmacychoice.com/mdx/drugpoint.cfm?docID=268590&letter=P&type=Trade%20Name&tradeName=Paxipam
Sources: https://www.drugs.com/mtm/paxipam.html
Curator's Comment: description was created based on several sources, including:
http://www.wikidoc.org/index.php/Halazepam | http://www.pharmacychoice.com/mdx/drugpoint.cfm?docID=268590&letter=P&type=Trade%20Name&tradeName=Paxipam
Halazepam is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. Halazepam is used to relieve anxiety, nervousness, and tension associated with anxiety disorders. Halazepam (Paxipam) is no longer commercially available in the United States. Common adverse effects are: hypotension, nausea, xerostomia, confusion, headache. Alcohol should be avoided while taking Paxipam as it causes drowsiness as well. Medications that also cause drowsiness should not be taken along with Paxipam. These include: Antidepressants, Pain relievers, Seizure medications, Muscle relaxants, Antihistamines, Sleeping pills and sedatives.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2093872 |
29.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | PAXIPAM Approved UseHalazepam is used to relieve anxiety, nervousness, and tension associated with anxiety disorders. Launch Date3.70137596E11 |
|||
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9264104 |
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
916 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6145534 |
40 mg 3 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
NORDAZEPAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
147 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6145534 |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
NORDAZEPAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
93 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6145534 |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
HALAZEPAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
137 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6145534 |
40 mg 3 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
HALAZEPAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
5863 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6145534 |
40 mg 3 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
NORDAZEPAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
796 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6145534 |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
NORDAZEPAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
347 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6145534 |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
HALAZEPAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
640 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6145534 |
40 mg 3 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
HALAZEPAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6145534 |
40 mg 3 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
HALAZEPAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
Effects of halazepam and diazepam on the motor coordination of geriatric subjects. | 1977 Jul 19 |
|
Pharmacology, efficacy, and adverse effects of halazepam, a new benzodiazepine. | 1982 Mar-Apr |
|
Direct injection micellar liquid chromatographic determination of benzodiazepines in serum. | 2002 Nov 25 |
|
Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality. | 2005 Dec |
|
[Consumption of inappropriate psychotropic drugs in residential homes for the elderly: comparative study between 2001 and 2006]. | 2008 Mar-Apr |
|
Community-based randomised controlled trial evaluating falls and osteoporosis risk management strategies. | 2008 Nov 4 |
|
Magnitude of potentially inappropriate prescribing in Germany among older patients with generalized anxiety disorder. | 2009 Jul 27 |
|
Inappropriate prescribing in the hospitalized elderly patient: defining the problem, evaluation tools, and possible solutions. | 2010 Apr 7 |
|
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010 Dec |
Patents
Sample Use Guides
20-40 mg 3-4 times a day; optimal doses range from 80-160 mg/day
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2867566
Competition curves generated by displacing [3H]-flunitrazepam binding, in sections of the forebrain, with halazepam showed IC50 values of 124.45 nM.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1012
Created by
admin on Fri Dec 15 15:10:10 UTC 2023 , Edited by admin on Fri Dec 15 15:10:10 UTC 2023
|
||
|
WHO-VATC |
QN05BA13
Created by
admin on Fri Dec 15 15:10:10 UTC 2023 , Edited by admin on Fri Dec 15 15:10:10 UTC 2023
|
||
|
WHO-ATC |
N05BA13
Created by
admin on Fri Dec 15 15:10:10 UTC 2023 , Edited by admin on Fri Dec 15 15:10:10 UTC 2023
|
||
|
DEA NO. |
2762
Created by
admin on Fri Dec 15 15:10:10 UTC 2023 , Edited by admin on Fri Dec 15 15:10:10 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
HALAZEPAM
Created by
admin on Fri Dec 15 15:10:10 UTC 2023 , Edited by admin on Fri Dec 15 15:10:10 UTC 2023
|
PRIMARY | |||
|
26412
Created by
admin on Fri Dec 15 15:10:10 UTC 2023 , Edited by admin on Fri Dec 15 15:10:10 UTC 2023
|
PRIMARY | RxNorm | ||
|
CHEMBL970
Created by
admin on Fri Dec 15 15:10:10 UTC 2023 , Edited by admin on Fri Dec 15 15:10:10 UTC 2023
|
PRIMARY | |||
|
DTXSID5023118
Created by
admin on Fri Dec 15 15:10:10 UTC 2023 , Edited by admin on Fri Dec 15 15:10:10 UTC 2023
|
PRIMARY | |||
|
1348
Created by
admin on Fri Dec 15 15:10:10 UTC 2023 , Edited by admin on Fri Dec 15 15:10:10 UTC 2023
|
PRIMARY | |||
|
245-425-4
Created by
admin on Fri Dec 15 15:10:10 UTC 2023 , Edited by admin on Fri Dec 15 15:10:10 UTC 2023
|
PRIMARY | |||
|
C010175
Created by
admin on Fri Dec 15 15:10:10 UTC 2023 , Edited by admin on Fri Dec 15 15:10:10 UTC 2023
|
PRIMARY | |||
|
SUB07992MIG
Created by
admin on Fri Dec 15 15:10:10 UTC 2023 , Edited by admin on Fri Dec 15 15:10:10 UTC 2023
|
PRIMARY | |||
|
DB00801
Created by
admin on Fri Dec 15 15:10:10 UTC 2023 , Edited by admin on Fri Dec 15 15:10:10 UTC 2023
|
PRIMARY | |||
|
7195
Created by
admin on Fri Dec 15 15:10:10 UTC 2023 , Edited by admin on Fri Dec 15 15:10:10 UTC 2023
|
PRIMARY | |||
|
m5894
Created by
admin on Fri Dec 15 15:10:10 UTC 2023 , Edited by admin on Fri Dec 15 15:10:10 UTC 2023
|
PRIMARY | Merck Index | ||
|
3339
Created by
admin on Fri Dec 15 15:10:10 UTC 2023 , Edited by admin on Fri Dec 15 15:10:10 UTC 2023
|
PRIMARY | |||
|
320YC168LF
Created by
admin on Fri Dec 15 15:10:10 UTC 2023 , Edited by admin on Fri Dec 15 15:10:10 UTC 2023
|
PRIMARY | |||
|
23092-17-3
Created by
admin on Fri Dec 15 15:10:10 UTC 2023 , Edited by admin on Fri Dec 15 15:10:10 UTC 2023
|
PRIMARY | |||
|
C61780
Created by
admin on Fri Dec 15 15:10:10 UTC 2023 , Edited by admin on Fri Dec 15 15:10:10 UTC 2023
|
PRIMARY | |||
|
31640
Created by
admin on Fri Dec 15 15:10:10 UTC 2023 , Edited by admin on Fri Dec 15 15:10:10 UTC 2023
|
PRIMARY | |||
|
100000084477
Created by
admin on Fri Dec 15 15:10:10 UTC 2023 , Edited by admin on Fri Dec 15 15:10:10 UTC 2023
|
PRIMARY |
ACTIVE MOIETY